A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)
PHASE1CompletedINTERVENTIONAL
Enrollment
64
Participants
Timeline
Start Date
January 20, 2023
Primary Completion Date
February 27, 2023
Study Completion Date
March 15, 2023
Conditions
Healthy
Interventions
DRUG
Molnupiravir
Oral Administration.
Trial Locations (1)
33143
QPS-MRA, LLC-Early Phase (Site 0002), South Miami
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT06615869 - A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011) | Biotech Hunter | Biotech Hunter